Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.56 |
| ▸ | TEK | Q02763 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.49 |
| ▸ | UCHL5 | Q9Y5K5 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30409985 | 1.00 | HDAC6 (0.56) | HDAC6TEKKDREPHB4UCHL5 | |
| SCHEMBL25349454 | 0.90 | HDAC6 (0.57) | HDAC6HDAC1 | |
| SCHEMBL31535160 | 0.90 | HDAC6 (0.57) | HDAC6HDAC1 | |
| SCHEMBL25349267 | 0.89 | HDAC6 (0.56) | HDAC6HDAC1 | |
| SCHEMBL31535159 | 0.89 | HDAC6 (0.57) | HDAC6TEKKDREPHB4HDAC1 | |
| SCHEMBL22557712 | 0.89 | HDAC6 (0.70) | HDAC6TEKKDREPHB4HDAC1 | |
| SCHEMBL25350687 | 0.89 | HDAC6 (0.57) | HDAC6TEKKDREPHB4HDAC1 | |
| SCHEMBL29402321 | 0.89 | HDAC6 (0.70) | HDAC6TEKKDREPHB4HDAC1 | |
| SCHEMBL24216054 | 0.88 | HDAC6 (0.67) | HDAC6KDRHDAC1 | |
| SCHEMBL29398947 | 0.88 | HDAC6 (0.67) | HDAC6KDRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| WO-2022013728-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885TEK 3885/4885KDR 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.